Mycophenolate mofetil in the therapy of uveitic macular edema--long-term results

Ocul Immunol Inflamm. 2012 Jun;20(3):203-11. doi: 10.3109/09273948.2012.665562. Epub 2012 Apr 10.

Abstract

Purpose: To assess the long-term efficacy of mycophenolate mofetil (MMF) in uveitic cystoid macular edema (CMO).

Methods: Thirty-eight uveitis patients with CMO treated with MMF with a follow-up of at least 5 years were analyzed. The patients were divided into two groups: group A, 24 patients with CMO that had occurred before initiation of MMF; group B, 14 patients who developed CMO for the first time during MMF.

Results: In group A, a complete remission of CMO without recurrences was observed in 12 of 24 patients (50%, rate: 0.12/patient-year). In group B, CMO occurred in 7 patients (50%) despite standard dosage of MMF, and in 7 patients (50%) during MMF dose reduction.

Conclusions: The results show that MMF is not always sufficiently effective as a long-term treatment for uveitic macular edema. Moreover, in some uveitis patients MMF cannot prevent new development of CMO.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Macular Edema / drug therapy*
  • Male
  • Middle Aged
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Recurrence
  • Treatment Outcome
  • Uveitis / drug therapy*
  • Visual Acuity / drug effects
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Mycophenolic Acid